USPTO Allows Key Patent for Exosome-Based Type 1 Diabetes Therapy
CELZ sits 89% above its 52-week low of $0.62 on elevated volume (11× avg).
Summary
The USPTO issued a Notice of Allowance for a patent covering exosome-based immunotherapy for Type 1 diabetes, deepening IP protection around the MyeloCelz platform. This adds a cell-free approach to the company's diabetes pipeline, complementing clinical-stage CELZ-101 and CELZ-201. The patent strengthens the moat around antigen-specific immune tolerance technology, a key differentiator in a market with no approved cure. The company plans to pursue licensing and partnership discussions leveraging the expanded IP. This follows recent financing moves, including a $4.5M warrant inducement and an S-3 shelf registration, as the company continues to fund its clinical programs.
At the time of this announcement, CELZ was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.62 to $6.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.